Mobile

A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma Studie bezpečno...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-015504-25

A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma Studie bezpečnosti a účinnosti Bendamustinu oproti Bendamustinu v kombinaci s GA101 u pacientů s non-Hodgkinským lymfomem refrakterním na Rituximab

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate clinical benefit in terms of PFS, as assessed by an IRF, for GA101 when used in combination with bendamustine compared with bendamustine alone in patients with indolent NHL refractory to prior rituximab-containing therapy

Critère d'inclusion

  • CD20+, indolent NHL

Liens